Frontage HoldingsFGHQF -3.57%58 EBITDA Margin % is 7.55% as of Dec. 2025, which is 72% below its 10-year median of 27.21. GuruFocus rates FGHQF with a GF Score™ of 58/100 and a GF Value™ of $0.21 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 938 Biotechnology companies, Frontage Holdings ranks better than 72.6% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Frontage Holdings's EBITDA for the
six
months ended in Dec. 2025 was $9.8 Mil. Frontage Holdings's Revenue for the
six
months ended in Dec. 2025 was $130.1 Mil. Therefore, Frontage Holdings's EBITDA margin for the quarter that ended in Dec. 2025 was 7.55%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Frontage Holdings EBITDA Margin % Related Terms
Frontage Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Frontage Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FGHQF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Frontage Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frontage Holdings EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Frontage Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Frontage Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Frontage Holdings (FGHQF) has a EBITDA Margin % of 7.55% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Frontage Holdings and its competitors. This is 72% below median its historical median of 27.21. Over the past decade, Frontage Holdings' EBITDA Margin % has ranged from 7.46 to 29.49. According to the industry distribution chart, Frontage Holdings ranks #257 out of 938 companies in the Biotechnology industry, placing it in the top 27.4%.
Is Frontage Holdings' EBITDA Margin % too high?
Frontage Holdings' current EBITDA Margin % of 7.55% is 72% below median its 10-year median of 27.21. Over the past 10 years, this metric has ranged from a low of 7.46 to a high of 29.49. Based on the distribution chart, Frontage Holdings ranks #257 out of 938 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Frontage Holdings has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Frontage Holdings' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Frontage Holdings ranks #257 out of 938 companies for EBITDA Margin %. This puts Frontage Holdings in the upper half of its industry. Historically, Frontage Holdings' own EBITDA Margin % has ranged from 7.46 to 29.49 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Frontage Holdings and its competitors. Frontage Holdings's current EBITDA Margin % is 7.55%, which is 72% below median its own 10-year median of 27.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Frontage Holdings stock overvalued right now?
Based on GuruFocus' analysis, Frontage Holdings (FGHQF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.21, compared to a current price of $0.14 — trading 35.7% below its estimated fair value. The current EBITDA Margin % is 7.55%, which is 72% below median its 10-year median of 27.21. Frontage Holdings' overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Frontage Holdings (FGHQF), the current EBITDA Margin % is 7.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Frontage Holdings (FGHQF) Overvalued in 2026?
Based on GuruFocus' analysis, Frontage Holdings stock appears to be undervalued.
The current stock price of $0.14 is trading 35.7% below its estimated GF Value™ of $0.21.
GuruFocus considers Frontage Holdings to be Possible Value Trap.
Key valuation signals for FGHQF:
EBITDA Margin %: 7.55% (72% below median its 10-year median of 27.21)
GF Value™: $0.21 vs. price of $0.14 (35.7% below fair value)
No single metric tells the full story. See the FGHQF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies. Its segments include North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe; and PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC. It derives majority of the revenue from North America and Europe segment. Geographically majority of the revenue is derived from USA and Canada.
58GF Score
Get the complete analysis for FGHQF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FGHQF has been successfully added to your 
